Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells

Prostate

Volumn 69, Issue 1, 2009, Pages 12-23

  Mori, Ryutaro ^a,b   Xiong, Shigang ^a   Wang, Qingcai ^a   Tarabolous, Chad ^a   Shimada, Hiroshi ^b   Panteris, Eleftherios ^c   Danenberg, Kathleen D ^d   Danenberg, Peter V ^a   Pinski, Jacek K ^a,e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c Response Genetics Ltd   (United Kingdom)

^d Response Genetics Inc   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Microarray; Neuroendocrine differentiation; Pathway analysis; Prostate cancer

Indexed keywords

ADRENALIN; GENISTEIN; INTERLEUKIN 6; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN LNCAP; CELL TRANSDIFFERENTIATION; DNA MICROARRAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MAPPING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOLECULAR PROBE; MORPHOLOGICAL TRAIT; NEUROSECRETORY CELL; OLIGONUCLEOTIDE PROBE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REFERENCE DATABASE; RNA HYBRIDIZATION; STUDENT T TEST; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; MALE; METABOLISM; NEUROSECRETION; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTICARCINOGENIC AGENTS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE, TUMOR; DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; HUMANS; INTERLEUKIN-6; MALE; NEUROSECRETORY SYSTEMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 58149326888     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20851     Document Type: Article

References (30)

1. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999;39(2):135-148.
2. Abrahamsson PA, Falkmer S, Falt K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker". Pathol Res Pract 1989;185(3):373-380.
3. Krijnen JL, Bogdanowicz JF, Seldenrijk CA, Mulder PG, van der Kwast TH. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997; 158(1):171-174.
4. Cohen RJ, Glezerson G, Haffejee Z, Afrika D. Prostatic carcinoma: Histological and immunohistological factors affecting prognosis. Br J Urol 1990;66(4):405-410.
5. Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27(7):683-687.
6. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997;80(11):2109-2119.
7. Shariff AH, Ather MH. Neuroendocrine differentiation in prostate cancer. Urology 2006;68(1):2-8.
8. Mori S, Murakami-Mori K, Bonavida B. Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun 1999; 257(2):609-614.
9. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000; 42(3):186-195.
10. Deeble PD, Murphy DJ, Parsons SJ, Cox ME. Interleukin-6-, cyclic, AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001;21(24):8471-8482.
11. Chen T, Cho RW, Stork PJ, Weber MJ. Elevation of cyclic adenosine 3',5'-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Res 1999;59(1):213-218.
12. Cox ME, Deeble PD, Bissonette EA, Parsons SJ. Activated 3',5'-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem 2000;275(18):13812-13818.
13. Zelivianski S, Verni M, Moore C, Kondrikov D, Taylor R, Lin MF. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta 2001;1539(1-2):28-43.
14. Pinski J, Wang Q, Quek ML, Cole A, Cooc J, Danenberg K, Danenberg PV. Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate 2006;66(11):1136-1143.
15. Hansson J, Abrahamsson PA. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol 2001;12(Suppl 2): S145-S152.
16. Jongsma J, Oomen MH, Noordzij MA, Romijn JC, van Der Kwast TH, Schroder FH, van Steenbrugge GJ. Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate 2000;42(1):34-44.
17. Wang Q, Horiatis D, Pinski J. Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation. Prostate 2004;61(3):253-259.
18. Wang Q, Horiatis D, Pinski J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int J Cancer 2004;111(4):508-513.
19. Chen Z, Komatsu K, Prestigiacomo A, Stamey TA. Addition of purified prostate specific antigen to serum from female subjects: Studies on the relative inhibition by alpha 2-macroglobulin and alpha 1-antichymotrypsin. J Urol 1996;156(4):1357-1363.
20. Chen JG, Yang CP, Cammer M, Horwitz SB. Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 2003;63(22):7891-7899.
21. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4(7):1086-1095.
22. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2005;11(18):6615-6624.
23. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334(Pt 2):297-314.
24. Culig Z, Bartsch G, Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol 2002;197(1 - 2):231 -238.
25. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001;12(1):33-40.
26. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19(21):2474-2488.
27. Sarfaraz S, Afaq F, Adhami VM, Malik A, Mukhtar H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem 2006;281(51):39480-39491.
28. Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie A, Hamburger AW. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proc Natl Acad Sci USA 2005;102(28):9890-9895.
29. Yin S, Li X, Meng Y, Finley RL Jr, Sakr W, Yang H, Reddy N, Sheng S. Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. J Biol Chem 2005;280(41):34985- 34996.
30. Ma H, Nguyen C, Lee KS, Kahn M. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 2005;24(22):3619-3631.